Slocum, Gordon & CO LLP Novartis Ag Transaction History
Slocum, Gordon & CO LLP
- $512 Million
- Q3 2024
A detailed history of Slocum, Gordon & CO LLP transactions in Novartis Ag stock. As of the latest transaction made, Slocum, Gordon & CO LLP holds 73 shares of NVS stock, worth $7,583. This represents 0.0% of its overall portfolio holdings.
Number of Shares
73
Previous 73
-0.0%
Holding current value
$7,583
Previous $7,000
14.29%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding NVS
# of Institutions
1,436Shares Held
137MCall Options Held
1.48MPut Options Held
1.55M-
Dodge & Cox San Francisco, CA12.2MShares$1.27 Billion0.85% of portfolio
-
Primecap Management CO Pasadena, CA12MShares$1.25 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.09MShares$841 Million0.23% of portfolio
-
Morgan Stanley New York, NY7.42MShares$771 Million0.06% of portfolio
-
Loomis Sayles & CO L P5.77MShares$599 Million0.87% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $223B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...